Innate Immune Environment in Ileal Pouch Mucosa: α5 Defensin Up-regulation as Predictor of Chronic/Relapsing Pouchitis

Journal of Gastrointestinal Surgery

Volumn 16, Issue 1, 2012, Pages 188-202

  Scarpa, Marco ^a   Grillo, Alessia ^b   Scarpa, Melania ^a   Brun, Paola ^b   Castoro, Carlo ^a   Pozza, Anna ^b   Cavallo, Donatella ^b   Faggian, Diego ^b   Ruffolo, Cesare ^c   D'Incà, Renata ^b   Bardini, Romeo ^b   Castagliuolo, Ignazio ^b   Angriman, Imerio ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c OSPEDALE CA FONCELLO   (Italy)

Author keywords

Chronic relapsing pouchitis; Defensins; Microbiota; Restorative proctocolectomy; Ulcerative colitis

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 5, HUMAN; ALPHA DEFENSIN 6, HUMAN; ALPHA-DEFENSIN 5, HUMAN; ALPHA-DEFENSIN 6, HUMAN; BETA DEFENSIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTOFERRIN; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL COUNT; CHEMISTRY; CHRONIC DISEASE; CLOSTRIDIUM DIFFICILE; COLON POUCH; ESCHERICHIA COLI; FECES; FEMALE; FOLLOW UP; GROWTH, DEVELOPMENT AND AGING; HUMAN; ILEITIS; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE MUCOSA; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; RECURRENT DISEASE; UPREGULATION;

ADULT; AGED; ALPHA-DEFENSINS; BETA-DEFENSINS; CHRONIC DISEASE; CLOSTRIDIUM DIFFICILE; COLONIC POUCHES; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; LACTOFERRIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POUCHITIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84855341561     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1720-6     Document Type: Article

References (51)

1. Onaitis MW, Mantyh C. Ileal pouch-anal anastomosis for ulcerative colitis and familial adenomatous polyposis: historical development and current status. Ann Surg 2003 238(6 Suppl): S42-S48.
2. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222: 120-7.
3. Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology 2004; 127: 1809-14.
4. Mahadevan U, Sandborn WJ. Diagnosis and treatment of pouchitis. Gastroenterology 2003; 124: 1636-50.
5. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study on the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131: 497-502.
6. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-5.
7. Mimura T, Rizzello F, Hleweg U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ; Gionchetti P, Campieri M, Kamm A. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16: 909-17.
8. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriothreapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-9.
9. Lim M, Sagar P, Finan P, Burke D, Schuster H. Dysbiosis and pouchitis. Br J Surg 2006; 93: 1325-34.
10. Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection-an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003 Feb; 46(2): 267-70.
11. Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig Dis Sci. 2006 Dec; 51(12): 2361-4.
12. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004; 47: 1519-25.
13. Duffy M. O'Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP, Kirwan WO. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002; 45: 384-8.
14. Ohge H. Furne JK, Springfield J, Rothenberger DA, Madoff RD, Levitt MD. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005; 48: 469-75.
15. Nicholls RJ, Banerjee AK. Pouchitis: risk factors, etiology, and treatment. World J Surg. 1998 Apr; 22(4): 347-51.
16. Scarpa M, Grillo A, Pozza A, Faggian D, Ruffolo C, Scarpa M, D'Incà R, Plebani M, Sturniolo GC, Castagliuolo I, Angriman I. TLR2 and TLR4 up-regulation and colonization of the ileal mucosa by Clostridiaceae spp. in chronic/relapsing pouchitis. J Surg Res 2011 169: 145-154.
17. Scarpa M, Grillo A, Faggian D, Ruffolo C, Bonello E, D'Incà R, Scarpa M, Castagliuolo I, Angriman I. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery 2011 150: 56-67.
18. Cario E. Bacterial interactions with cells of the intestinal mucosa: toll-like receptors and NOD2. Gut 2005; 54: 1182-93.
19. Toiyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today. 2006; 36(3): 287-90.
20. Haller D, Russo MP, Sartor RB, Jobin C. IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem 2002; 277: 38168-78.
21. Ganz T, Lehrer RI. Defensins. Curr Opin Immunol 1994; 6: 584-9.
22. Fellermann K, Stange EF. Defensins-innate immunity at the epithelial frontier. Eur J Gastroenterol Hepatol 2001; 13: 771-6.
23. Lehrer RI, Barton A, Daher KA, et al. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 1989; 84: 553-61.
24. Kagan BL, Selsted ME, Ganz T, et al. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A 1990; 87: 210-14.
25. Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996; 271: 2935-40.
26. Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992; 267: 23216-25.
27. Cunliffe RN, Rose FRAJ, Keyte J, et al. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 2001; 48: 176-85.
28. Wehkamp J, Schwind B, Herrlinger KR, Baxmann S, Schmidt K, Duchrow M, Wohlschlager C, Feller AC, Stange EF, Fellermann K. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci 2002; 47: 1349-1355.
29. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001; 10: 445-56.
30. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human b-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999; 163: 6718-24.
31. Scarpa M, van Koperen PJ, Ubbink DT, Hommes DW, ten Kate FJW, Bemelman WA. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 2007; 94: 534-45.
32. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: pouchitis activity index. Mayo Clinic Proc 1994; 69: 409-15.
33. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-402.
34. Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, Yadav SP, Crabb JW, Ganz T, Bevins CL. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol. 2002 Jun; 3(6): 583-90.
35. Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods. 2006 May; 65(2): 335-45.
36. Ruffolo C, Scarpa M, Faggian D, Pozza A, Navaglia F, D'Inca R, Hoxha P, Romanato G, Polese L, Sturniolo GC, Plebani M, D'Amico DF, Angriman I. Cytokine network in rectal mucosa in perianal Crohn's disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis 2008; 14: 1406-12.
37. Scarpa M, D'Incà R, Basso D, Ruffolo C, Polese L, Bertin E, Luise A, Frego M, Plebani M, Sturniolo GC, D'Amico DF, Angriman I. Faecal lactoferrin and calprotectin after ileo-colonic resection for Crohn's disease. Dis Colon Rectum 2007; 50: 861-9.
38. International Council for Standardization in Haematology (Expert Panel on Blood Rheology). ICSH recommendations for measurement of erythrocyte sedimentation rate. J Clin Pathol 1993; 46: 198-203.
39. Dominici R, Luraschi P, Franzini C. Measurement of C-reactive protein: two high sensitivity methods compared. J Clin Lab Anal 2004; 18: 280-4.
40. Brooks SP, Lampi BJ, Sarwar G, Botting HG. A comparison of methods for determining total body protein. Anal Biochem 1995; 226: 26-30.
41. Henderson AR. Assessing test accuracy on its clinical consequence: a primer for receiver operative characteristics curve analysis. Ann Clin Biochem 1993; 30: 521-539.
42. Kiehne K, Brunke G, Wegner F, Banasiewicz T, Fölsch UR, Herzig KH. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol 2006; 21; 12(7): 1056-1062.
43. Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S, Schroder JM. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000; 22: 714-721.
44. Aldhous MC, Noble CL, Satsangi J (2009) Dysregulation of human b-defensin-2 protein in inflammatory bowel disease. PLoS ONE 4(7): e6285. doi: 10. 1371/journal. pone. 0006285.
45. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, et al. Reduced Paneth cell a-defensins in ileal Crohn's disease. Proc Nat Acad Sci USA 2005; 102: 18129-18134.
46. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaeffeler E, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal a-defensin expression. Gut 2004; 53: 1658-1664.
47. Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007; 56: 1240-1247.
48. Noble CL, Abbas AR, Cornelius J, Lees CW, Ho GT, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 2008; 57: 1398-1405.
49. Shepherd NA, Healey CJ, Warren BF, Richman PI, Thomson WH, Wilkinson SP. Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir. Gut 1993; 34: 101-105.
50. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-693.
51. Wehkamp J, Wang G, Kubler I, Nuding S, Gregorieff A, Schnabel A, Kays RJ, Fellermann K, Burk O, Schwab M, Clevers H, Bevins CL, Stange EF. The Paneth cell α-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol, 2007, 179: 3109-3118.